Skye Bioscience Inc.(US:SKYE) Globenewswire·2025-12-20 12:39Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness of its drug nimacimab [4][6]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives made false and misleading statements regarding nimacimab, claiming it was more effective than it actually is [6]. - Specific allegations include that nimacimab's clinical, regulatory, and commercial prospects were overstated, leading to materially false public statements [6]. Group 3: Stock Price Impact - Following the announcement on October 6, 2025, that nimacimab did not achieve its primary endpoint in a clinical study, Skye's stock price fell by $2.85 per share, or 60%, closing at $1.90 per share [7].